KBC Group
XENE icon

KBC Group’s Xenon Pharmaceuticals XENE Stock Holding History

KBC Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.79M Hold
129,010
– – 0.02% 408
2026
Q1 		$7.5M Buy
129,010
+126,230
+4,541% +$5.82M 0.02% 392
2025
Q4 		$125K Buy
2,780
+909
+49% +$38.2K ﹤0.01% 1148
2025
Q3 		$75K Hold
1,871
– – ﹤0.01% 1452
2025
Q2 		$59K Sell
1,871
-890
-32% -$29K ﹤0.01% 1528
2025
Q1 		$93K Buy
2,761
+19
+0.7% +$721 ﹤0.01% 1526
2024
Q4 		$107K Buy
2,742
+780
+40% +$32.2K ﹤0.01% 1511
2024
Q3 		$77K Hold
1,962
– – ﹤0.01% 1465
2024
Q2 		$76K Buy
+1,962
New +$78.4K ﹤0.01% 1350

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

KBC Group's XENE Position: Q2 2026 in Review

KBC Group held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 129,010 shares worth $7.79M. The position accounts for 0.02% of the portfolio, ranked #408.

KBC Group first reported a position in XENE in Q2 2024 and has held it in 9 quarters since. 96 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • KBC Group held 129,010 shares of Xenon Pharmaceuticals worth $7.79M as of Q2 2026.
  • KBC Group left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
  • Xenon Pharmaceuticals made up 0.02% of KBC Group's portfolio in Q2 2026, its #408 holding.
  • KBC Group first reported a position in Xenon Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 96 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.